Freshfields advised Camurus on its collaboration and license agreement with Eli Lilly. The agreement grants Lilly exclusive, worldwide rights to the research, development, manufacture and commercialization of long-acting incretin products for cardiometabolic health based on Camurus’ FluidCrystal technology. The agreement comprises up to four Lilly proprietary drug compounds.*

In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic health, Camurus is eligible to receive up to $290 million in upfront, development, and regulatory milestone payments as well as $580 million in sales-based milestone payments and tiered mid-single digit royalties on global net product sales.

The Freshfields team was led by partners Adam Golden and Jeff Jay and included associate Juliana Zhang along with contributions from Sora Park.

*Selected from dual GIP and GLP-1 receptor agonists, triple GIP, glucagon and GLP-1 receptor agonists, and an option to include amylin receptor agonists.